DOCSLIB.ORG

Ments and a Sham Court Verdict

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ments and a Sham Court Verdict Holiday Reading Book review Spilling the beans on the pharmaceutical industry At this point, CMAJ gets a walk-on Side Effects: A Prosecutor, a part in the book. In 2004, CMAJ re- Whistleblower, and a Bestselling vealed a confidential memo in its news Antidepressant on Trial pages that proved the makers of parox- Alison Bass Algonquin Books of Chapel Hill; 2008 etine “knew they were holding back in- 260 pp $24.95 ISBN978 1-56512-553-7 formation and that what they were do- ing was wrong,” as a lawyer in the New Our Daily Meds: How the Pharmaceutical York attorney general’s office put it 1 Companies Transformed Themselves into later. The CMAJ’s news story pro- slick Marketing Machines and Hooked the vided the attorney general’s office with Nation on Prescription Drugs the requisite smoking gun in a case that Melody Petersen turned out to have broad implications. Sarah Crichton Books, Farrar, Straus and In a settlement, Glaxo agreed to post its Giroux; 2008 clinical trial results, jump-starting the 414 pp $26.00 ISBN 978-0-374-22827-9 international movement to register all clinical trials. Writing with a novelist’s touch and he past 4 years have witnessed honing her material for its underside, a wave of books condemning Bass has produced a gripping who- T the pharmaceutical industry for dunit replete with dead bodies, hidden unethical practices, but in 2008, Algonquin Books of Chapel Hill documents, public monies spent on Pharma began to turn the corner, nonexistent studies and even a sham transformed by clinical trial registries, dustry’s bad behaviour in Africa. Here court verdict. bans on ghostwritten papers and the heroine is Rose Firestein, a nearly Our Daily Meds, a treatise on the (south of the border, at least) trans- blind, diabetic woman in her 50s who overuse and misuse of brand-name parency regarding companies’ submis- toiled behind the headlines as an assis- medications, also has corpses, but it’s sions to regulators. The transformation tant attorney general, digging for evi- closer to advocacy journalism than nar- is in many ways a credit to whistle- dence that would prove the company’s rative nonfiction. For Petersen, the blowers and to those who acted on bad behaviour was criminal. Through pharmaceutical companies cause “far their evidence. Two new books from scanning the literature and meeting too much needless harm” through their US journalists — Side Effects by for- with a whistle-blower, she discovered “profiteering,” and she refers so often mer Boston Globe reporter, Alison the hidden studies showing that paroxe- to the “medicine merchants” and “med- Bass and Our Daily Meds by Melody tine doesn’t work against depression in icine marketers” with their “hoards of Petersen, who covered Pharma for the children and adolescents and jumped cash” and “cash-filled coffers” that, at New York Times — expand our under- on them. “I think we can argue that by times, Our Daily Meds becomes an un- standing of this tarnished industry by not fully disclosing all of its research enlightening, one-sided screed. But introducing us to a few of the individ- uals who found themselves battling against it from the inside and chose to Bass has produced a gripping whodunit come forward. Side Effects lays out the compelling drama of how New York’s then- replete with dead bodies, hidden docu- attorney general Elliot Spitzer — be- fore his downfall while state governor ments and a sham court verdict. — charged GlaxoSmithKline with fraud for deceiving doctors about its results, Glaxo is guilty of fraud under what lifts it up, and will stay with you, blockbuster antidepressant, paroxetine the New York statute!” she told a col- are the individual characters she depicts (Paxil). Though the case is compli- league. But the attorney general’s of- and the dramas they’re caught in. Iowa cated, the book draws readers along in fice had never sued a drug company on is Petersen’s home state and she went what could almost be a screenplay for a those grounds and, initially, none of her there to be a fly-on-the-wall as drug North American version of the Con- superiors thought it was possible. company sales reps subtly suggested stant Gardener, the award-winning Firestein had to convince the team and that consumers swallow new pills. At DOI:10.1503/cmaj.081496 2005 film about the pharmaceutical in- Bass lets us watch her do it. the medical centre in Storm Lake, CMAJ • DECEMBER 2, 2008 • 179(12) 1309 © 2008 Canadian Medical Association or its licensors Holiday Reading Iowa, population 20 000, she lunched few. Petersen gives concrete evidence Franklin taped the voice mails and filed with a group of women who were of this via the story of David Franklin, a suit under the United States false claims being encouraged to worry about sleep- scientist who went to work for Parke act, a unique mechanism that can pro- less nights. One said she thought her Davis in 1996 as a sales rep touting the vide an incentive to whistle-blowers antidepressant was keeping her awake, who discover their employers are rip- but the luncheon speaker, a rep for ping off the government. The company Sanofi-Aventis, makers of the best- eventually paid the government nearly a selling sleeping pill, zolpidem (Am- half-billion dollars and, as the whistle- bien), wasn’t discussing drug side ef- blower in the case, Franklin’s share was fects; she was describing insomnia, a nearly $30 million. Petersen, angry that condition she said could result in for- none of those behind the gabapentin getfulness, moodiness, heart disease, scheme were sanctioned, argues for a obesity, “psychotic issues” and car reform plan that would throw a few crashes. “I don’t mean to scare you,” pharma executives in jail, but leaves the rep told the assembled women, but readers wondering about Franklin. How of course, she did. Her job, it seems, did he fare when he faced his former su- was to leave the women, half of whom periors in court? Why was he the only were seniors, terrified of insomnia and employee who was driven to complain besieging their doctors for zolpidem, publicly about the company’s practices? described in kits left in the lunchroom And, most important, why did he blow as the country’s “#1 prescribed sleep the whistle instead of just walking aid.” What the women weren’t told is away? that for many patients, especially the The value of both these books is that elderly, the risks of sleeping pills out- they underscore how crucial such a de- weigh their benefits. Zolpidem’s side cision can be. The change that’s com- effects — daytime sleepiness, amnesia, Farrar, Straus and Giroux ing to Pharma has been brought about and dizziness — can lead to falls and by the converging efforts of several fractures and it has such high potential benefits of the antiseizure medication, Rose Firesteins and David Franklins, for addiction that its label warns doc- gabapentin (Neurontin) and found him- watching, listening and spilling the tors not to prescribe it for more than 10 self morally repulsed by his job. A beans. days. group of Parke Davis executives calling Our Daily Meds demonstrates that themselves the New Product Committee Miriam Shuchman MD many of the deaths and injuries that re- instructed Franklin and his fellow reps Psychiatrist sult from prescription drugs aren’t acci- to promote gabapentin for conditions Toronto, Ont. dents; they’re the direct result of a mul- where there’s minimal evidence that it titiered system of inducements that drug works, then told them to be careful to companies hurl at doctors, consumers, communicate solely through the corpo- REFERENCE 1. Kondro W, Sibbald, B. Drug company experts ad- magazine publishers, hospitals, pharma- rate voice mail program since anything vised staff to withhold data about SSRI use in chil- cies, and elected officials, to name a in writing could be audited. Instead, dren. CMAJ 2004;170:783 Holiday Reading Acknowledgements Our call for submissions to the Holiday Reading section — a literary deviation from our usual Holiday Review — drew an unprecedented number of submissions, resulting in some extremely difficult judging decisions. Thank you to our esteemed panel of reading enthusiasts: Erin Driscoll, Jesse Craig, Kate Schissler, Kelly Clarke, Patricia Lightfoot and Wayne Kondro. Thanks also to our designer Carole Lalonde. And a very special thank you to everyone who submitted a manuscript. Wishing you many hours of enjoyable reading over the holidays, Barbara Sibbald Deputy Editor, News and Humanities 1310 CMAJ • DECEMBER 2, 2008 • 179(12) © 2008 Canadian Medical Association or its licensors.
Load more

Recommended publications
  • Medicine Safety “Pharmacovigilance” Fact Sheet
    MINISTRY OF MEDICAL SERVICES MINISTRY OF PUBLIC HEALTH AND SANITATION PHARMACY AND POISONS BOARD MEDICINE SAFETY “PHARMACOVIGILANCE” FACT SHEET What is medicine safety? Medicine safety, also referred to as Pharmacovigilance refers to the science of collecting, monitoring, researching, assessing and evaluating information from healthcare providers and patients on the adverse effects of medicines, biological products, herbals and traditional medicines. It aims at identifying new information about hazards, and preventing harm to patients. What is an Adverse Drug Reaction? The World Health Organization defines an adverse drug reaction (ADR) as "A response to a drug which is noxious and unintended, and which occurs at doses normally used or tested in man for the prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function". Simply put, when the doctor prescribes you medicines, he expects the desirable effects of them. The undesired effects of the medicines is the ADR or, commonly known as “side effects”. An adverse drug reaction is considered to be serious when it is suspected of causing death, poses danger to life, results in admission to hospital, prolongs hospitalization, leads to absence from productive activity, increased investigational or treatment costs, or birth defects. Age, gender, previous history of allergy or reaction, race and genetic factors, multiple medicine therapy and presence of concomitant disease processes may predispose one to adverse effects. Why monitor adverse drug reactions? Before registration and marketing of a medicine, its safety and efficacy experience is based primarily on clinical trials. Some important adverse reactions may not be detected early or may even be rare.
    [Show full text]
  • AVANDIA (Rosiglitazone Maleate Tablets), for Oral Use Ischemic Cardiovascular (CV) Events Relative to Placebo, Not Confirmed in Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION ----------------------- WARNINGS AND PRECAUTIONS ----------------------- These highlights do not include all the information needed to use • Fluid retention, which may exacerbate or lead to heart failure, may occur. AVANDIA safely and effectively. See full prescribing information for Combination use with insulin and use in congestive heart failure NYHA AVANDIA. Class I and II may increase risk of other cardiovascular effects. (5.1) • Meta-analysis of 52 mostly short-term trials suggested a potential risk of AVANDIA (rosiglitazone maleate tablets), for oral use ischemic cardiovascular (CV) events relative to placebo, not confirmed in Initial U.S. Approval: 1999 a long-term CV outcome trial versus metformin or sulfonylurea. (5.2) • Dose-related edema (5.3) and weight gain (5.4) may occur. WARNING: CONGESTIVE HEART FAILURE • Measure liver enzymes prior to initiation and periodically thereafter. Do See full prescribing information for complete boxed warning. not initiate therapy in patients with increased baseline liver enzyme levels ● Thiazolidinediones, including rosiglitazone, cause or exacerbate (ALT >2.5X upper limit of normal). Discontinue therapy if ALT levels congestive heart failure in some patients (5.1). After initiation of remain >3X the upper limit of normal or if jaundice is observed. (5.5) AVANDIA, and after dose increases, observe patients carefully for signs • Macular edema has been reported. (5.6) and symptoms of heart failure (including excessive, rapid weight gain; • Increased incidence of bone fracture was observed in long-term trials. dyspnea; and/or edema). If these signs and symptoms develop, the heart (5.7) failure should be managed according to current standards of care.
    [Show full text]
  • Pharmaceutical Sales Representatives
    [Chapter 4, 28 April] Chapter 4 Pharmaceutical sales representatives Andy Gray, Jerome Hoffman and Peter R Mansfield The presence of pharmaceutical industry sales representatives almost seems a fact of life at many modern medical centres and universities around the world. Many medical and pharmacy students come into contact with pharmaceutical industry sales representatives during their training. Later on in the careers of many health professionals, encounters with sales representatives can occur on a daily basis, taking up a substantial portion of a busy health professional s time. However, health professionals have a choice in the matter - they may choose not to see pharmaceutical sales representatives at all or they may attempt to manage such interactions.’ This chapter aims to provide information to help you make up your own mind on this issue. This choice has important consequences for health professionals practice and patients, so requires careful consideration. ’ Aims of this chapter By the end of the session based on this chapter, you should be able to answer a series of questions on your interactions with sales representatives: In what ways, if any, might I hope to benefit from meeting with sales representatives? How are sales representatives selected, trained, supported and managed? What information do sales representatives provide? How might contact with sales representatives influence me in a positive or negative way? Should I have contact with sales representatives at all? Is it possible, if I choose to have contact with sales representatives, to minimise the potential harm and maximise the potential benefit for my professional development and practice? This chapter presents evidence that we believe can be helpful in addressing these questions, and ends with a series of activities that will allow students to work on the issue in more depth.
    [Show full text]
  • Alison Bass Curriculum Vitae Current Affiliations • Associate Professor Of
    Alison Bass Curriculum Vitae Current Affiliations Associate Professor of Journalism, West Virginia University 2012-present Author, Freelance Writer and Blogger 2008-present Journalism Experience Author of forthcoming book, Getting Screwed: Sex Workers and the Law (Fall 2015) Getting Screwed takes a wide-ranging historic look at prostitution in the United States. It weaves the true stories of sex workers (past and present) together with the latest research in exploring the advisability of decriminalizing adult prostitution. To read more about this project, visit www.sexworkandthelaw.com/. Author of Side Effects: A Prosecutor, a Whistleblower and a Bestselling Antidepressant on Trial Side Effects won the NASW Science in Society Award and garnered critical acclaim from many quarters, including The New York Review of Books, The Boston Globe and The Washington Post. Published by Algonquin Books in 2008, Side Effects tells the true story of three people who exposed the deception behind the making of a bestselling drug. To read more about the book, visit www.alison-bass.com. Journalist-Blogger 2008-present My blog, at http://www.sexworkandthelaw.com/blog/ is an ongoing discussion about sex work and public health. I have also written blogs for The Huffington Post and opinion pieces for The Boston Globe about various topics including scientific misconduct and sex work. Alicia Patterson Foundation 2007-2008 Won a prestigious Alicia Patterson Fellowship to write Side Effects, a book about scientific fraud and conflicts of interest in the medical/pharmaceutical industry. CIO magazine, Executive Editor 2000-2006 Wrote and edited feature-length articles and columns for CIO, an award-winning business magazine that covers information technology.
    [Show full text]
  • Side Effects in Education
    What works may hurt: Side effects in education Yong Zhao Journal of Educational Change ISSN 1389-2843 J Educ Change DOI 10.1007/s10833-016-9294-4 1 23 Your article is protected by copyright and all rights are held exclusively by Springer Science +Business Media Dordrecht. This e-offprint is for personal use only and shall not be self- archived in electronic repositories. If you wish to self-archive your article, please use the accepted manuscript version for posting on your own website. You may further deposit the accepted manuscript version in any repository, provided it is only made publicly available 12 months after official publication or later and provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at link.springer.com”. 1 23 Author's personal copy J Educ Change DOI 10.1007/s10833-016-9294-4 What works may hurt: Side effects in education Yong Zhao1 Ó Springer Science+Business Media Dordrecht 2017 Abstract Medical research is held as a field for education to emulate. Education researchers have been urged to adopt randomized controlled trials, a more ‘‘scien- tific’’ research method believed to have resulted in the advances in medicine. But a much more important lesson education needs to borrow from medicine has been ignored. That is the study of side effects. Medical research is required to investigate both the intended effects of any medical interventions and their unintended adverse effects, or side effects.
    [Show full text]
  • The Pharma Barons: Corporate Law's Dangerous New Race to the Bottom in the Pharmaceutical Industry
    Michigan Business & Entrepreneurial Law Review Volume 8 Issue 1 2018 The Pharma Barons: Corporate Law's Dangerous New Race to the Bottom in the Pharmaceutical Industry Eugene McCarthy University of Illinois Follow this and additional works at: https://repository.law.umich.edu/mbelr Part of the Business Organizations Law Commons, Consumer Protection Law Commons, Food and Drug Law Commons, and the Rule of Law Commons Recommended Citation Eugene McCarthy, The Pharma Barons: Corporate Law's Dangerous New Race to the Bottom in the Pharmaceutical Industry, 8 MICH. BUS. & ENTREPRENEURIAL L. REV. 29 (2018). Available at: https://repository.law.umich.edu/mbelr/vol8/iss1/3 This Article is brought to you for free and open access by the Journals at University of Michigan Law School Scholarship Repository. It has been accepted for inclusion in Michigan Business & Entrepreneurial Law Review by an authorized editor of University of Michigan Law School Scholarship Repository. For more information, please contact [email protected]. THE PHARMA BARONS: CORPORATE LAW’S DANGEROUS NEW RACE TO THE BOTTOM IN THE PHARMACEUTICAL INDUSTRY Eugene McCarthy* INTRODUCTION......................................................................................... 29 I. THE RACE TO THE BOTTOM AND THE RISE OF THE ROBBER BARONS ..................................................................................... 32 A. Revising the Corporate Codes............................................ 32 B. The Emergence of Nineteenth-Century Lobbying ............. 37 C. The Robber
    [Show full text]
  • Death of a Sales Model, Or Not: Perspectives on The
    ACKNOWLEDGEMENTS We are indebted to Bryce Davis for his organization and leadership, which made this compendium possible. Thank you also to Geoff Lewis, Kate Spears, and Patrick Taaffe, our editors, and to Alizah Herman for design. And finally, we would like to thank our clients and friends, for sharing with us their stories on where they’ve been and their thoughts on the path ahead, as they lead their companies and colleagues through this period of change. Global/NA Head of Pharmaceutical and Medical Products (PMP) Michael Silber EU/HEAD OF PMP Vivian Hunt ASIA PACIFIC/HEAD OF PMP Rajesh Parekh For questions or more information, please contact Bryce Davis ([email protected]) Chicago Office New Jersey Office Orange County Office Stamford Office 21 South Clark Street 600 Campus Drive 131 Innovation Drive Three Landmark Suite 2900 Florham Park, NJ Suite 200 Square Chicago, IL 60603 07932 Irvine, CA 92617 Suite 100 Stamford, CT 06901 Los Angeles Office New York Office Silicon Valley Office 400 South Hope Street 5 East 52nd Street 3075A Hansen Way Suite 800 21st Floor Palo Alto, CA 94304 Los Angeles, CA 90071 New York, NY 10022 CONTENTS Preface 02 Introduction David Quigley Articles 03 The Few, The Proud, The Super-Productive How a ‘smart field force’ can better drive sales Laura Moran and David Quigley 09 Organization Men Understanding the challenges and serving the needs of corporatized healthcare providers Bhawana Malhotra, Nick Mills, Laura Moran, and David Quigley 15 The More the Merrier? ‘Account ownership’ and other engagement
    [Show full text]
  • Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients by Ben Goldacre
    RCSIsmjbook review Bad Pharma: How drug companies mislead doctors and harm patients by Ben Goldacre Reviewed by Eoin Kelleher, RCSI medical student Paperback: 448 pages Publisher: Fourth Estate, London Published 2012 ISBN: 978-0-00-735074-2 Dr Ben Goldacre earned his reputation for his 2008 book Bad to affect doctors’ prescribing habits (although most doctors claim Science and his column in the Guardian newspaper of the same that their own practices have never been affected, just those of their name. In both he provides an entertaining, accessible and colleagues). Even journals, which are considered to be an unbiased well-researched exposé of poor scientific practices. Compared to source of medical knowledge, are not free from this – journal articles his first book, which played charlatans such as Gillian McKeith are regularly ghost-written by employees of drug companies and an and homoeopathists for laughs, Bad Pharma is a much more eminent academic is invited to put their name to it; this appears in sombre read. However, as a piece of investigative journalism, and the journal, again without disclosure. a resource for students, doctors and patients, it is invaluable. Drugs are tested by the people who Food for thought Goldacre opens by making a claim that: “Drugs are tested by the manufacture them, in poorly designed people who manufacture them, in poorly designed trials, on trials, on hopelessly small numbers of hopelessly small numbers of weird, unrepresentative patients, and unrepresentative patients, and analysed analysed using techniques which are flawed by design, in such a way that exaggerate the benefits of treatments.
    [Show full text]
  • Pharmaceutical Companies Need a Dose of Corporate Social Responsibility
    Minnesota Journal of Law, Science & Technology Volume 9 Issue 2 Article 7 2008 Side Effects of Corporate Greed: Pharmaceutical Companies Need a Dose of Corporate Social Responsibility Martin L. Hirsch Follow this and additional works at: https://scholarship.law.umn.edu/mjlst Recommended Citation Martin L. Hirsch, Side Effects of Corporate Greed: Pharmaceutical Companies Need a Dose of Corporate Social Responsibility, 9 MINN. J.L. SCI. & TECH. 607 (2008). Available at: https://scholarship.law.umn.edu/mjlst/vol9/iss2/7 The Minnesota Journal of Law, Science & Technology is published by the University of Minnesota Libraries Publishing. MARTIN L. HIRSCH, "AUTHENTIC HAPPINESS, SELF-KNOWLEDGE AND LEGAL POLICY," 9(2) MINN. J.L. SCI. & TECH. 607-636 (2008). Side Effects of Corporate Greed: Pharmaceutical Companies Need a Dose of Corporate Social Responsibility Martin L. Hirsch* I. INTRODUCTION “The point is, ladies and gentleman, that greed . for lack of a better word . is good. Greed is right. Greed works. Greed clarifies, cuts through, and captures the essence of the evolutionary spirit.”1 When it comes to health care and pharmaceuticals, greed is not good. In the world of health care, where patients rely on their doctors to do what is best for them, there is no place for greed.2 Corporate governance in pharmaceutical companies that focuses on the shareholder’s bottom line is completely inconsistent with health care, medicine and access to pharmaceuticals, where the patient should come first.3 This Article discusses how the corporate governance of pharmaceutical companies negatively affects health care and access to medicine world wide.4 *© 2008 Martin L.
    [Show full text]
  • Adverse Effects of Vaccines Evidence and Causality
    REPORT BRIEF AUGUST 2011 .For more information visit www.iom.edu/vaccineadverseeffects Adverse Effects of Vaccines Evidence and Causality Immunizations are a cornerstone of the nation’s efforts to protect people from a host of infectious diseases. As required by the Food and Drug Admin- istration, vaccines are tested for safety before they enter the market, and their performance is continually evaluated to identify any risks that might appear over time. Vaccines are not free from side effects, or “adverse effects,” but most are very rare or very mild. Importantly, some adverse health problems following a vaccine may be due to coincidence and are not caused by the vaccine. As part of the evaluation of vaccines over time, researchers assess evidence to deter- As part of the evaluation of mine if adverse events following vaccination are causally linked to a specific vaccines over time, researchers vaccine, and if so, they are referred to as adverse effects. Under the National assess evidence to determine if Childhood Vaccine Injury Act of 1986, Congress established the National Vac- adverse events following cine Injury Compensation Program (VICP) to provide compensation to peo- vaccination are causally linked to ple injured by vaccines. Anyone who thinks they or a family member—often a a specific vaccine, and if so, they are referred to as adverse effects. child—has been injured can file a claim. The Health Resources and Services Administration (HRSA), the agency within the Department of Health and Human Services that administers VICP, can use evidence that demonstrates a causal link between an adverse event and a vaccine to streamline the claim process.
    [Show full text]
  • Impacts of Pharmaceutical Marketing on Healthcare Services in the District of Columbia
    Impacts of Pharmaceutical Marketing on Healthcare Services in the District of Columbia Prepared by The George Washington University School of Public Health and Health Services Washington, DC for the District of Columbia Department of Health June 15, 2009 TABLE OF CONTENTS I. EXECUTIVE SUMMARY......................................................................................................................................3 HEALTHCARE IN THE DISTRICT OF COLUMBIA...........................................................................................................3 FINDINGS ON PHARMACEUTICAL MARKETING IN THE DISTRICT................................................................................4 RECOMMENDATIONS .................................................................................................................................................6 II. THE ROLE OF PHARMACEUTICALS IN HEALTHCARE ..........................................................................7 PHARMACEUTICALS AND HEALTHCARE IN THE DISTRICT OF COLUMBIA...................................................................8 III. CONCERNS ABOUT PHARMACEUTICAL MARKETING.......................................................................13 PRESCRIPTION-DRUG EXPENDITURES ......................................................................................................................13 EFFECTIVENESS AND SIDE EFFECTS.........................................................................................................................14 OFF-LABEL PRESCRIBING........................................................................................................................................15
    [Show full text]
  • Harmful Side Effects: How Drug Companies Undermine Global Health
    Harmful side effects How drug companies undermine global health www.oxfam.org.uk OXFAM BRIEFING NOTE – SEPTEMBER 2018 New Oxfam research shows that four pharmaceutical companies – Abbott, Johnson & Johnson, Merck and Pfizer – systematically hide their profits in overseas tax havens. This activity could deprive developing countries of $112m (around £88m) every year – money that is urgently needed to meet the health needs of people in these countries – while charging very high prices for their products. In the UK, these four companies may be underpaying around £124m of tax each year. These corporations also deploy massive lobbying operations to influence trade, tax and health policies in their favour and give their damaging behaviour greater apparent legitimacy. Tax dodging, high prices and political influencing by pharmaceutical companies exacerbate the yawning gap between rich and poor, between men and women, and between advanced economies and developing ones. © Oxfam GB September 2018 This paper was written by Oliver Pearce and Mohga Kamal-Yanni, based on the Oxfam report, Prescription for Poverty: Drug companies as tax dodgers, price gougers, and influence peddlers. Oxfam acknowledges the assistance of Chris Worrall, Claire Spoors and Francesca Rhodes in its production. It is part of a series of papers written to inform public debate on development and humanitarian policy issues. For further information on the issues raised in this paper please email [email protected] This publication is copyright but the text may be used free of charge for the purposes of advocacy, campaigning, education, and research, provided that the source is acknowledged in full. The copyright holder requests that all such use be registered with them for impact assessment purposes.
    [Show full text]